3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma, Ewing
4
Gliosarcoma
3
Glioblastoma
3
Central Nervous System Neoplasms
3
Astrocytoma
3
Sarcoma
2
Brain Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Rare Diseases
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms, Connective Tissue
1
Neoplasms, Bone Tissue
1
Neoplasms by Histologic Type
1
Neoplasms
1
Meningioma
1
Medulloblastoma
1
Liver Neoplasms
1
Glioma, Subependymal
1
Glioma
1
Familial ependymoma
1
Ependymoma
1
Choroid Plexus Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Doxorubicin
3
lentiviral minigene vaccine of COVID-19 coronavirus
1
eltrombopag
1
camrelizumab
1
apatinib
1
Vinorelbine
1
Trabectedin
1
Temozolomide
1
Observation
1
Methotrexate
1
Irinotecan
1
FANG vaccine
1
Dexamethasone
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Connective and Soft Tissue
×
FANG vaccine
×
Sarcoma
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts